PMID: 26236730 Gwyer D, Wragg NM, Wilson SL
[119] conducted a phase II clinical trial in patients with NASH, that is, a placebo-controlled trial of subcutaneous sommarutide in the treatment of NASH, and found that sommarutide treatment resulted in a significantly higher proportion of patients in remission of NASH compared with placebo
I., Tsoukas, M., Unger, J., Karsbl, J
Training Approach: Resistance training is not optional on this protocol
Meet the Green Relief Health Provider Lauren Nawrocki, DNP, CRNP Lauren Nawrocki is a doctorally prepared nurse practitioner and founder of Green Relief Health
GLP-1 Insurance Coverage Landscape GLP-1 drugs coverage depends on payer type (commercial/employer plans, Medicare, Medicaid) and on the indication (diabetes vs obesity)